

Florence S H Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2042540/publications.pdf>

Version: 2024-02-01

161
papers

13,337
citations

28274

55
h-index

23533

111
g-index

168
all docs

168
docs citations

168
times ranked

7036
citing authors

#	ARTICLE	IF	CITATIONS
1	Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1031-1040.e3.	4.4	7
2	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , 2022, 28, 560-570.	2.4	11
3	Acute-on-Chronic Liver Failure Clinical Guidelines. <i>American Journal of Gastroenterology</i> , 2022, 117, 225-252.	0.4	90
4	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. <i>Liver International</i> , 2022, , .	3.9	2
5	Acute-on-Chronic Liver Failure. <i>American Journal of Gastroenterology</i> , 2022, 117, 831-834.	0.4	2
6	Management of hepatorenal syndrome in liver cirrhosis: a recent update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211026.	3.2	20
7	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3612-3618.	2.3	15
8	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1661-1669.e2.	4.4	14
9	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 565-572.e5.	4.4	7
10	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
11	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021, 70, 531-536.	12.1	178
12	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , 2021, 384, 818-828.	27.0	235
13	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. <i>Liver Transplantation</i> , 2021, 27, 1343-1347.	2.4	25
14	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048.	7.3	311
15	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 2699-2713.	7.3	27
16	REPLY:. <i>Hepatology</i> , 2021, 74, 2916-2917.	7.3	0
17	COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy. <i>Hepatology</i> , 2021, 74, 1074-1080.	7.3	14
18	Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2021, 75, 1010-1012.	3.7	1

#	ARTICLE	IF	CITATIONS
19	Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. American Journal of Gastroenterology, 2021, 116, 336-346.	0.4	17
20	Historical Aspects of Ascites and the Hepatorenal Syndrome. Clinical Liver Disease, 2021, 18, 14-27.	2.1	0
21	Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. Nephrology Dialysis Transplantation, 2020, 35, 1554-1561.	0.7	22
22	Pathways of hepatic and renal damage through nonclassical activation of the renin-angiotensin system in chronic liver disease. Liver International, 2020, 40, 18-31.	3.9	42
23	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology, 2020, 159, 1715-1730.e12.	1.3	65
24	Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. Journal of Vascular and Interventional Radiology, 2020, 31, 1256-1262.e3.	0.5	5
25	Reply. Liver Transplantation, 2020, 26, 1541-1542.	2.4	0
26	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. Liver Transplantation, 2020, 26, 799-810.	2.4	13
27	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Digestive Diseases and Sciences, 2020, 65, 2571-2579.	2.3	17
28	Acute kidney injury: prediction, prognostication and optimisation for liver transplant. Hepatology International, 2020, 14, 167-179.	4.2	14
29	Model for End-Stage Liver Disease Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. Hepatology, 2020, 72, 1747-1757.	7.3	42
30	Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. Liver Transplantation, 2020, 26, 651-661.	2.4	19
31	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver International, 2020, 40, 2385-2393.	3.9	5
32	Management of Ascites. , 2020, , 11-30.		0
33	Latest Treatment of Acute Kidney Injury in Cirrhosis. Current Treatment Options in Gastroenterology, 2020, 18, 281-294.	0.8	7
34	Cirrhosis; Acute Kidney Injury. , 2020, , 514-525.		0
35	Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). Antiviral Therapy, 2019, 24, 35-44.	1.0	12
36	Refractory Ascites in Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, 40-47.	0.4	46

#	ARTICLE	IF	CITATIONS
37	Reply. Liver Transplantation, 2019, 25, 1586-1587.	2.4	0
38	Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. <i>Nutrients</i> , 2019, 11, 2379.	4.1	5
39	SAT-141-The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start?. <i>Journal of Hepatology</i> , 2019, 70, e692-e693.	3.7	3
40	Ascites and Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , 2019, 23, 659-682.	2.1	20
41	Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acuteâ€œChronic Liver Failure. <i>Clinical Liver Disease</i> , 2019, 14, 92-97.	2.1	11
42	SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation. <i>Journal of Hepatology</i> , 2019, 70, e691-e692.	3.7	1
43	Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2339-2346.e1.	4.4	24
44	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , 2019, 25, 870-880.	2.4	55
45	Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. <i>Hepatology</i> , 2019, 70, 450-451.	7.3	5
46	Outcomes After Listing for Liver Transplant in Patients With Acuteâ€œChronic Liver Failure: The Multicenter North American Consortium for the Study of Endâ€œStage Liver Disease Experience. <i>Liver Transplantation</i> , 2019, 25, 571-579.	2.4	53
47	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
48	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 599-606.	0.4	17
49	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1091-1100.	0.4	41
50	Treatment of Oesophageal Varices in Liver Cirrhosis. <i>Digestion</i> , 2019, 99, 261-266.	2.3	12
51	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 45-51.	8.1	48
52	An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 293-305.	3.0	25
53	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 756-765.e3.	4.4	89
54	Utility of shearâ€œwave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. <i>Journal of Clinical Ultrasound</i> , 2018, 46, 311-318.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Acuteâ€“Chronic Liver Failure: Getting Ready for Prime Time?. Hepatology, 2018, 68, 1621-1632.	7.3	86
56	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. American Journal of Gastroenterology, 2018, 113, 556-563.	0.4	87
57	NACSELD acuteâ€“chronic liver failure (NACSELDâ€“ACLF) score predicts 30â€“day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67, 2367-2374.	7.3	197
58	Unâ€“precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver International, 2018, 38, 1785-1792.	3.9	14
59	IDDF2018-ABS-0067â€“...Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study. , 2018, , .		0
60	Renal Failure in Cirrhosis. , 2018, , 262-280.e5.		1
61	Hepatorenal syndrome. Nature Reviews Disease Primers, 2018, 4, 23.	30.5	172
62	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1339.	0.4	44
63	Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. , 2018, 38, 1785.		1
64	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. Digestive Diseases and Sciences, 2017, 62, 768-776.	2.3	19
65	New diagnostic criteria and management of acute kidney injury. Journal of Hepatology, 2017, 66, 860-861.	3.7	35
66	Terlipressin Improves Renal Function and Reverses Hepatorenalâ€“Syndrome in Patients With Systemic Inflammatoryâ€“Responseâ€“Syndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 266-272.e1.	4.4	53
67	Acute kidney injury in liver cirrhosis: new definition and application. Clinical and Molecular Hepatology, 2016, 22, 415-422.	8.9	65
68	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1821-1830.e6.	4.4	61
69	The 3â€“month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology, 2016, 64, 200-208.	7.3	189
70	Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Digestive Diseases and Sciences, 2016, 61, 3084-3092.	2.3	23
71	Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?. Hepatology International, 2016, 10, 390-393.	4.2	0
72	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016, 150, 1579-1589.e2.	1.3	225

#	ARTICLE	IF	CITATIONS
73	Diagnosing and treating renal disease in cirrhotic patients. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 253-66.	2.2	11
74	Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 300-307.	2.4	122
75	Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1441-1446.	1.0	23
76	Variations in albumin use in patients with cirrhosis: An AASLD members survey. <i>Hepatology</i> , 2015, 62, 1923-1924.	7.3	18
77	High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end-stage liver disease. <i>Liver Transplantation</i> , 2015, 21, 881-888.	2.4	59
78	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	12.1	405
79	A cut-off serum creatinine value of 1.5 mg/dl for AKI "To be or not to be. <i>Journal of Hepatology</i> , 2015, 62, 741-743.	3.7	25
80	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	3.7	571
81	Definition and Diagnosis of Acute Kidney Injury in Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 539-547.	1.9	7
82	Treatment to Improve Acute Kidney Injury in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2015, 13, 235-248.	0.8	4
83	The evolving concept of acute kidney injury in patients with cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 711-719.	17.8	35
84	Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 389-395.	2.8	66
85	Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e1-e5.	0.4	22
86	Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 753-759.e2.	4.4	105
87	Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis. <i>Hepatology</i> , 2014, 60, 455-457.	7.3	10
88	Speckle tracking echocardiography in cirrhosis: is it ready for prime time?. <i>Hepatology International</i> , 2014, 8, 10-13.	4.2	0
89	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , 2014, 60, 250-256.	7.3	456
90	EASL Recognition Awardee for 2014: Prof. Tilman Sauerbruch. <i>Journal of Hepatology</i> , 2014, 61, 469-471.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , 2013, 28, 301-305.	2.9	26
92	The impact of acute kidney injury in cirrhosis: does definition matter?. <i>Gut</i> , 2013, 62, 1091.2-1092.	12.1	6
93	New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. <i>Gastroenterology</i> , 2013, 145, 1280-1288.e1.	1.3	221
94	Acute kidney injury in decompensated cirrhosis. <i>Gut</i> , 2013, 62, 131-137.	12.1	205
95	Acute renal dysfunction in liver cirrhosis. <i>Gastroenterology and Hepatology</i> , 2013, 9, 830-2.	0.1	2
96	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. <i>Gut</i> , 2012, 61, 108-116.	12.1	121
97	Recent advances in our understanding of hepatorenal syndrome. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 382-391.	17.8	91
98	Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. <i>Critical Care</i> , 2012, 16, R23.	5.8	145
99	Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , 2012, 56, 2328-2335.	7.3	357
100	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , 2012, 61, 1219-1225.	12.1	81
101	Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 11-20.	2.8	68
102	Hepatorenal Syndrome: Do the Vasoconstrictors Work?. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 581-598.	2.2	6
103	Renal Diseases and the Liver. <i>Clinics in Liver Disease</i> , 2011, 15, 39-53.	2.1	13
104	Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. <i>Gut</i> , 2011, 60, 702-709.	12.1	359
105	Medical management of ascites. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1269-1283.	1.8	9
106	Beta-blockers in cirrhosis: Friend and foe?. <i>Hepatology</i> , 2010, 52, 811-813.	7.3	43
107	Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 937-947.	3.9	161
108	Vaptans for Ascites – Chances and Risks. <i>Frontiers of Gastrointestinal Research</i> , 2010, , 91-101.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. <i>Gut</i> , 2010, 59, 381-386.	12.1	83
110	Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290.	3.7	78
111	Cirrhotic cardiomyopathy. <i>Hepatology International</i> , 2009, 3, 294-304.	4.2	172
112	The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt. <i>American Journal of Gastroenterology</i> , 2009, 104, 2458-2466.	0.4	160
113	Hepatorenal syndrome: Current management. <i>Current Gastroenterology Reports</i> , 2008, 10, 22-29.	2.5	11
114	Effects of satavaptan, a selective vasopressin V ₂ receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. <i>Hepatology</i> , 2008, 48, 204-213.	7.3	183
115	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2008, 84, 662-670.	1.8	504
116	Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2007, 133, 825-834.	1.3	494
117	Drug Insight: the role of albumin in the management of chronic liver disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 43-51.	1.7	68
118	Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. <i>Hepatology</i> , 2007, 47, 160-168.	7.3	41
119	Portal hypertensive gastropathy. <i>Gastroenterology and Hepatology</i> , 2007, 3, 428-73.	0.1	3
120	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006, 5, 5-15.	1.5	40
121	The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. <i>Hepatology</i> , 2006, 44, 640-649.	7.3	4
122	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006, 44, 1535-1542.	7.3	349
123	The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006, 5, 5-15.	1.5	15
124	Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges?. <i>Hepatology</i> , 2005, 42, 533-535.	7.3	13
125	Management of Ascites. , 2005, , 301-317.		1
126	Hepatorenal Syndrome: Are We Doing Better?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004, 18, 121-122.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , 2004, 40, 55-64.	7.3	369
128	Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. <i>MedGenMed: Medscape General Medicine</i> , 2004, 6, 9.	0.2	4
129	A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. <i>Hepatology</i> , 2003, 37, 182-191.	7.3	269
130	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266.	7.3	744
131	The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , 2003, 124, 634-641.	1.3	424
132	Does Losartan Work After All?. <i>American Journal of Gastroenterology</i> , 2003, 98, 1222-1224.	0.4	4
133	The Role of Liver Biopsy in the Management of Patients with Liver Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 651-654.	1.7	1
134	Excess nitric oxide in preascites: another piece in the puzzle. <i>American Journal of Gastroenterology</i> , 2002, 97, 2167-2169.	0.4	3
135	Liver and kidney diseases. <i>Clinics in Liver Disease</i> , 2002, 6, 981-1011.	2.1	16
136	The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. <i>Hepatology</i> , 2002, 35, 1449-1458.	7.3	42
137	THE PATHOPHYSIOLOGIC BASIS FOR THE TREATMENT OF CIRRHOTIC ASCITES. <i>Clinics in Liver Disease</i> , 2001, 5, 819-832.	2.1	9
138	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , 2001, 101, 621-628.	4.3	68
139	Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , 2001, 101, 621.	4.3	23
140	New challenge of hepatorenal syndrome: Prevention and treatment. <i>Hepatology</i> , 2001, 34, 1242-1251.	7.3	78
141	The hyperdynamic circulation in cirrhosis. , 2001, 89, 221-231.		127
142	Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , 2001, 96, 2442-2447.	0.4	90
143	Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. <i>Hepatology</i> , 2000, 31, 207-210.	7.3	435
144	Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites ²² Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada.. <i>American Journal of Medicine</i> , 1999, 106, 315-322.	1.5	63

#	ARTICLE	IF	CITATIONS
145	Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. <i>Clinical Science</i> , 1999, 96, 467-474.	4.3	6
146	Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , 1999, 97, 259-267.	4.3	109
147	Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , 1999, 97, 259.	4.3	38
148	The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. <i>Gastroenterology</i> , 1998, 115, 397-405.	1.3	42
149	REVIEW: The controversy over the pathophysiology of ascites formation in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 437-444.	2.8	17
150	Effects of Sodium Status on the Venous Response to Noradrenaline Infusion in Pre-Ascitic Cirrhosis. <i>Clinical Science</i> , 1995, 88, 525-531.	4.3	8
151	Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. <i>Hepatology</i> , 1995, 21, 1238-1247.	7.3	366
152	Transjugular intrahepatic portosystemic shunt for refractory ascites: Tipping the sodium balance. <i>Hepatology</i> , 1995, 22, 358-364.	7.3	36
153	Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites. <i>Annals of Internal Medicine</i> , 1995, 122, 816.	3.9	223
154	Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. <i>Gastroenterology</i> , 1995, 108, 1820-1827.	1.3	68
155	Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis*1. <i>Hepatology</i> , 1995, 21, 717-724.	7.3	4
156	Central blood volume in cirrhosis: Measurement with radionuclide angiography. <i>Hepatology</i> , 1994, 19, 312-321.	7.3	83
157	Renal response to a saline load in well-compensated alcoholic cirrhosis. <i>Hepatology</i> , 1994, 20, 873-881.	7.3	51
158	Central blood volume in cirrhosis: Measurement with radionuclide angiography. <i>Hepatology</i> , 1994, 19, 312-321.	7.3	12
159	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. <i>Hepatology</i> , 1993, 18, 519-528.	7.3	19
160	Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. <i>Gastroenterology</i> , 1993, 104, 884-889.	1.3	55
161	Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. <i>Hepatology</i> , 1993, 18, 519-528.	7.3	1